Αποτελέσματα Αναζήτησης
PROLEUKIN is a lymphocyte growth factor indicated for: (1) treatment of adults with metastatic renal cell carcinoma; (2) treatment of adults with metastatic melanoma. PROLEUKIN is available through a Speciality Distribution network. Click below to access more details on how to order. Ordering Guide. Questions about PROLEUKIN?
23 Μαΐ 2019 · Proleukin treatment is associated with impaired neutrophil function (reduced chemotaxis) and with an increased risk of disseminated infection, including sepsis and bacterial endocarditis. Consequently, preexisting bacterial infections should be adequately treated prior to initiation of Proleukin therapy.
4 Μαΐ 2020 · Proleukin is the first and only approved recombinant IL-2 indicated for the treatment of adults with metastatic renal cell carcinoma (mRCC) or metastatic melanoma (mM) by the US Food and Drug Administration (FDA).
23 Οκτ 2022 · Here, we assess whether LD IL2 is safe in UC patients, expands Tregs, and affects underlying immune mechanisms. We conducted an open-label phase 1b/2a 8-week induction trial of daily subcutaneous LD IL2 (Proleukin, Prometheus) in patients with moderate to severe UC.
Proleukin R Observational Study to Evaluate the Treatment Patterns and Clinical Response in Malignancy (PROCLAIM SM) is the largest observational clinical database of high-dose interleukin-2 (HD IL-2)-treated patients in the US.
Medscape - Indication-specific dosing for Interleukin 2, Proleukin (aldesleukin), frequency-based adverse effects, comprehensive interactions, contraindications, pregnancy & lactation...
10 Οκτ 2013 · Proleukin (aldesleukin) for injection is a recombinant human interleukin-2 for treatment in adults with mM and mRCC, a type of kidney cancer. Proleukin therapy is a form of immunotherapy that...
